APRE

Aprea Therapeutics Inc

APRE.US aprea.com + Research + Basket
CIK 0001781983
Employees 8
Phone 215 948 4119
Fiscal year end December
IPO Oct 03, 2019
Address 3805 Old Easton Road, Doylestown, PA, United States, 18902
0.51
+0.06 (+14.25%)
USD · NASDAQ
52-week range
0.41
1.47
Trading at 10% of the 52-week range
Market Cap
5.65M
P/E Ratio
0.00
Forward P/E
0.00
Book Value
3.11
Div. Yield
N/A
% Institutions
18.83%
% Insiders
9.17%

1 Year

-61.7%

3 Year

-85.7%

10 Year

-99.9%
Description

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidates are APR-1051, an orally bioavailable small-molecule inhibitor of WEE1 kinase that is in Phase 1 clinical trial for the treatment of patients with advanced solid tumors with biomarkers and ATRN-119, an ATR inhibitor, which is in Phase 1/2a clinical trial for solid tumor indications. The company is headquartered in Doylestown, Pennsylvania.

Actions

Add an action for APRE.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Dr. Oren Gilad Ph.D. Co-Founder, CEO, President & Director 1968
Mr. John P. Hamill CPA Senior VP, CFO, Principal Accounting Officer & Secretary 1964
Dr. Lars B. Abrahmsen Ph.D. Senior VP & Chief Scientific Officer 1957
Mr. Brian Wiley Senior Vice President of Corporate Development & Strategy 1968
Dr. Michel Afargan Ph.D. Head of Pharmacology Development NA
Mr. Ze'ev Weiss B.Sc., C.P.A. Chief Business Advisor 1962
Dr. Eugene P. Kennedy F.A.C.S., M.D. Chief Medical Advisor 1969
Ms. Andrea Epstein Controller NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
Dec 10, 2025 John P Hamill N/A Purchase 5.00K $1.17 $5.85K SEC
Dec 10, 2025 Marc Duey N/A Purchase 21.46K $1.17 $25.11K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
AIGH Capital Management, LLC 1.02M Jun 30, 2026 8.07% $0.05 0.00%
Nantahala Capital Management, LLC 411.52K Jun 30, 2026 3.27% $0.01 100.00%
Vestal Point Capital LP 350.00K Jun 30, 2026 2.78% $0.01 0.00%
Sphera Funds Management Ltd. 270.00K Jun 30, 2026 2.14% $0.03 0.00%
Renaissance Technologies Corp 105.80K Jun 30, 2026 0.84% $0.00 321.51%
Geode Capital Management, LLC 74.87K Jun 30, 2026 0.59% $0.00 -37.15%
Citadel Advisors Llc 58.60K Jun 30, 2026 0.47% $0.00 0.00%
BNP Paribas Arbitrage, SA 45.21K Jun 30, 2026 0.36% $0.00 13.55%
Diadema Partners LP 44.91K Jun 30, 2026 0.36% $0.00 0.00%
Vanguard Fiduciary Trust Co 38.46K Jun 30, 2026 0.31% $0.00 0.00%
Susquehanna International Group, LLP 34.94K Jun 30, 2026 0.28% $0.00 168.39%
Morgan Stanley - Brokerage Accounts 25.83K Jun 30, 2026 0.21% $0.00 15.67%
Vanguard Capital Management, LLC 22.88K Jun 30, 2026 0.18% $0.00 16.61%
LPL Financial Corp 16.05K Jun 30, 2026 0.13% $0.00 -23.75%
HighTower Advisors, LLC 13.86K Jun 30, 2026 0.11% $0.00 0.00%
Northern Trust Corp 13.71K Jun 30, 2026 0.11% $0.00 0.00%
Persistent Asset Partners Limited 11.49K Jun 30, 2026 0.09% $0.00 0.00%
XTX Topco Ltd 10.57K Jun 30, 2026 0.08% $0.00 0.00%
BlackRock Inc 7.17K Jun 30, 2026 0.06% $0.00 -15.65%
Tower Research Capital LLC 3.59K Jun 30, 2026 0.03% $0.00 -29.98%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Fidelity Extended Market Index 59.62K 0.47% ▼ 0.53% Aug 31, 2026
2 Fidelity Total Market Index 7.20K 0.06% ▲ 0.00% Aug 31, 2026
3 Fidelity Series Total Market Index 5.85K 0.05% ▲ 0.00% Aug 31, 2026
4 BlackRock Diversified Equity Alpha Inst 289.00 0.00% ▲ 0.00% Jul 31, 2026

Financial Highlights

▼
Market Cap: $5.65M
EBITDA: $-13.20M
Book Value: $3.11
Earnings/Share: $-0.95
Profit Margin: 0.00%
Operating Margin: -255,025.51%
ROA (TTM): -27.73%
ROE (TTM): -46.15%
Revenue (TTM): $5.19K
Revenue/Share (TTM): $0.00
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): -98.40%

Valuation Metrics

Enterprise Value: $-34.71M
Trailing P/E: 0.00
Forward P/E: 0.00

Shares Statistics

Shares Outstanding: 12.59M
Shares Float: 7.90M
% Insiders: 9.17%
% Institutions: 18.83%
Short % Float: 4.29%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$285.76K
Cost of Goods Sold
adjust
$-21.72K
Gross Profit
subtotal
$264.04K
SG&A
adjust
$-6.48M
R&D
adjust
$-7.04M
Operating Income
subtotal
$-13.23M
Other / Non-Operating Items
adjust
$634.27K
Net Income
subtotal
$-12.60M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about APRE.US!